Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

Trial Profile

Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs AAV-IFNA2B gene therapy Medgenics (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Aevi Genomic Medicine
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 09 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jun 2012, according to a Medgenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top